Venetoclax dose adjustment due to drug-drug interactions: a case report and literature review

Abstract

The primary aim of the study is to discuss the potential interactions between venetoclax and common drugs used in department of hematology and the corresponding effects on the efficacy and safety of venetoclax treatment. Here, we report an acute myeloid leukemia patient treated with venetoclax and posaconazole, and the dose of venetoclax was adjusted due to drug interactions. Clinical pharmacists actively participated in treatment of this patient to provide pharmacy care to assist clinicians to identify the venetoclax-induced liver function impairment and give timely management. The case reported here is hoped to provide reference for clinical venetoclax treatment in patients with such disease. Clinical pharmacists should actively participate in clinical treatment, actively screen potential drug interactions, strengthen cooperation and communication with doctors, provide patients with high-quality pharmaceutical services, and establish clinical pharmacists’ status in the multidisciplinary treatment of tumor.

Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management

“…Venetoclax is also a substrate and inhibitor of ABC-family transporters P-gp and BCRP [ 95 ]. When administered as a single 100 mg dose on healthy volunteers, venetoclax increased digoxin C max by 35% and AUC 0–∞ by 9%, suggesting that, in a clinical setting, venetoclax can affect the clearance of digoxin and possibly other P-gp substrates.…”